Genmab — Januar 2014
-
dara+revlamid - likely very important revenue generator in future
-
nej han sagde the next months tror jeg
-
det sluttede han med - men han lovede noget i næste uge lidt før
-
vi kan da håbe
-
det lyder som om han gentager dara+rev data fra ASH
-
nu humax-tissue factor
-
han viser vist den grafik solsen fandt frem om adc'ens virkning
-
most powerful we have ever seen in pre-clinical
-
nu platform
-
duobody antibodies har samme half life some de antibodies, der indgår
-
Jannsen har 6 aktive duobody programmer
-
partnerne sponsorerer alle omk på duobody - også GEN interne omkostninger
-
relevant when looking at burnrate
-
nu hexa
-
applicable to a large number of diseases
-
can repurpose candidates - can supercharge candidates
-
expected to show robust growth in future
-
nu financial guidance
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind